🇺🇸 FDA
Company

Fulcrum

Fulcrum Therapeutics

FULC pharma USA

Quick answer

Fulcrum is a pharma company (FULC) headquartered in CAMBRIDGE, MA, USA with 9 tracked pipeline programs.

Pipeline (9)

project

Losmapimod

Facioscapulohumeral Muscular Dystrophy (FSHD)

Phase 3 · small_molecule · terminated

2 trials project

Losmapimod oral tablet

COVID-19

Phase 3 · small_molecule · terminated

1 trials project

ACE393

Campylobacter Infection

Phase 2 · mab · active

1 trials project

Losmapimod

Facioscapulohumeral Muscular Dystrophy 1

Phase 2 · small_molecule · terminated

1 trials project

Losmapimod oral tablet

Facioscapulohumeral Muscular Dystrophy (FSHD)

Phase 2 · small_molecule · completed

1 trials project

Pociredir

Sickle Cell Disease

Phase 2 · small_molecule · active

2 trials project

FTX-6058/placebo oral capsule(s)

Healthy Adult Subjects

Phase 1 · small_molecule · completed

1 trials project

Losmapimod 15 mg oral tablet

Healthy Adult Subjects

Phase 1 · small_molecule · completed

1 trials project

Pociredir oral capsule(s)

Sickle Cell Disease

Phase 1 · small_molecule · completed

1 trials

Patents (8)

patent

US 12109198

Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11819554

Compositions and methods for modulating FMR1 expression

Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11590111

Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11479770

Use of p38 inhibitors to reduce expression of DUX4

Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11291659

P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatme

Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10973805

Macrocyclic azolopyridine derivatives as EED and PRC2 modulators

Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10537560

P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatme

Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10342786

P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatme

Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)